Clinical trial
Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
NCT00316433 · Swedish Medical Center, Other · Terminated
Key facts
| NCT number | NCT00316433 |
|---|---|
| Title | Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer |
| Official title | Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer |
| Lead sponsor | Swedish Medical Center, Other |
| Collaborators | Sanofi-Synthelabo Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Irinotecan (CPT-11), Oxaliplatin (Eloxatin) |
| Enrollment | 24 |
| Start date | Feb 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Apr 20, 2006 |
| Last update posted | Apr 5, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: